3 programs in oncology are currently under development and available for licensing or collaboration. For these projects with high added value and attractive business opportunity, OriBase Pharma is looking for worldwide partners to pursue a co-development or direct licensing arrangement.
The 3 programs available are :
- ORB0001 (Small molecules, regulatory preclinical stage) : Best-in-class MTKI
- ORB0003 (Biological therapeutics, regulatory preclinical stage) : First-in-class Anti-AXL monoclonal antibodies
- ORB0004 (Small molecules, lead optimization stage) : First-in-class AXL/FLT3/ARK5 and AXL/FLT3/NTRK inhibitors
Click on the links below to discover these projects.